Our study investigates the key determinants of Chief Executive Officer (CEO) gross pay in Indian pharmaceutical companies listed under BSE-S&P Healthcare index (Bombay Stock Exchange- Standard & Poor) using a longitudinal sample of 33 firms over 10-year period from 2008-09 to 2017-18. This amounts to 330 firm-years data. We probe the effect of firm performance, corporate governance, human capital, and tournament characteristics on the gross pay of CEOs. Profit after tax, Return on Assets, and Market Capitalization are found to be significant determinants of CEOs' total pay. Larger boards and companies having remuneration committees are found to be rewarding their CEOs with higher pay. Insidereffect on total pay is observed to be significant. CEO's lifetime experience has significant positive impact on the total pay. Gini's coefficient is below the alarming level of 0.5 for 93.8 per cent of firm-years indicating non-criticality of pay disparity between CEO and Key Managerial Personnel (KMP), in spite of large number of firms being led by promoter-directors.